In vitro evaluation of leukemia inhibitory factor receptor antagonists as candidate therapeutics for inflammatory arthritis

Journal of Interferon and Cytokine Research

Volumn 27, Issue 4, 2007, Pages 281-289

  Jazayeri, Jalal A ^a   De Weerd, Nicole ^b   Raye, Warren ^b   Kivivuori, Satu ^b   Zabihi, Ebrahim ^b   Carroll, Graeme J ^b  

^a MONASH UNIVERSITY   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; CYTOKINE RECEPTOR; GLYCOPROTEIN GP 130; GLYCOSAMINOGLYCAN; HAPTOGLOBIN; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR RECEPTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR ANTAGONIST; LIF 05; MH35 BD; ONCOSTATIN M; PROTEIN SUBUNIT; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CARTILAGE; CELL ASSAY; CELL PROLIFERATION; CHONDROPROTECTION; CONCENTRATION PROCESS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INFLAMMATION; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RECEPTOR BINDING; RHEUMATOID ARTHRITIS; SWINE; TREATMENT INDICATION;

ANIMALS; ARTHRITIS, RHEUMATOID; CELL LINE; CYTOKINE RECEPTOR GP130; GLYCOSAMINOGLYCANS; HUMANS; HYDROXYPROLINE; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN M; RECEPTORS, OSM-LIF; RECOMBINANT FUSION PROTEINS; SWINE;

SUS;

EID: 34249077832     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.0138     Document Type: Article

References (40)

1. Hilton DJ, Nicola NA, Gough N, Metcalf D. Resolution and purification of three distinct factors produced by Krebs ascites cells which have differentiation and inducing activity on murine myeloid leukemic cell lines. J. Biol. Chem. 1988;263:9238-9243.
2. Taga T, Kishimoto T. Gp130 and interleukin-6 family of cytokines. Annu. Rev. Immunol. 1997;15:797-819.
3. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-361.
4. Mezzasoma L, Biondi R, Benedetti C, Floridi C, Ciurnelli R, Falcinelli F, Onorato M, Scaringi L, Marconi P, Rossi R. In vitro production of leukemia inhibitory factor (LIF) by HepG2 hepatoblastoma cells. J. Biol. Regul. Homeost. Agents 1993;7:126-132.
5. Gearing DP, Comeau MR, Friend DJ, Gimpel SD, Thut CJ, McGourty J, Brasher KK, King JA, Gillis S, Mosley B. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 1992;13:255:1434-1437.
6. Hermanns HM, Radtke S, Haan C, Schmitz-Van de Leur H, Tavernier J, Heinrich PC, Behrmann I. Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130. J. Immunol. 1999;163:6651-6658.
7. Heymann D, Goddard A, Raher S. Leukemia inhibitory factor (LIF) and oncastatin M (OSM) high affinity binding require additional receptor subunits besides gp130 and gp190. Cytokine 1998;8:197-205.
8. Mosley B, De Imust C, Friend D, Boiani N, Thoma B, Park, LS, Csman D. Dual oncostatin M (OSM) receptors. J. Biol. Chem. 1996;271:32635-32643.
9. Gadient RA, Patterson PH. Leukemia inhibitory factor, interleukin 6 and other cytokines using gp130 transducing receptor: role in inflammation and injury. Stem Cells 1999;17:127-137.
10. Hopkins SJ, Humphreys M, Jason MI. Cytokines in synovial fluid. The presence of biologically active and immunoreactive IL-1. Clin. Exp. Immunol. 1988;72:422-427.
11. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996;14:397-440.
12. Carroll GJ, Bell MC, Chapman HM, Mills JN, Robinson WF. Leukemia inhibitory factor induces leukocyte infiltration and cartilage proteoglycan degradation in goat joints. J. Interferon Cytokine Res. 1995;15:567-573.
13. Langdon C, Kerr C, Hassen M, Hara T, Arsenault AL, Richards CD. Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. Am. J. Pathol. 2000;157:1187-1196.
14. Lotz M, Moats T, Villiger PM. Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis. J. Clin. Invest. 1992;90:888-896.
15. Schlaak JF, Pfers I, Meryer zum Buschenfelde KH, Markker-Hermann E. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin. Exp. Rheum. 1996;14:155-162.
16. Waring PM, Carroll GJ, Kandish DA, Buiraki G, Metcalf D. Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1993;35:911-915.
17. Feldmann, M. Development of anti-.TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2002;2:364-371.
18. Moreland LW, Emery P, eds. TNFα Inhibition in the Treatment of Rheumatoid Arthritis. London: Martin Dunitz Taylor & Francis Group, 2003.
19. Hui W, Bell MC, Carroll GJ. Oncostatin M stimulates resorption and inhibits synthesis of proteoglycan in pig articular cartilage explants. Cytokine 1996;8:495-500.
20. Hui W, Bell MC, Carroll GJ. Detection of oncostatin M in synovial fluid from patients with rheumatoid arthritis. Ann. Rheum. Dis. 1997;56:184-187.
21. Carroll GJ, Bell MC. Leukemia inhibitory factor stimulates proteoglycan resorption in pig articular cartilage. Rheumatol. Int. 1993;13:5-8.
22. Carroll GJ, Bell MC, Chapman HM, Mills JN, Robinson WF. Leukemia inhibitory factor (LIF) induces leukocyte infiltration and cartilage proteoglycan degradation in goat joints. J. Interferon Cytokine Res. 1995;15:567-573.
23. Hui W, Bell MC, Carroll GJ. Modulation of cartilage proteoglycan metabolism by LIF binding protein. Cytokine 1998;10:220-228.
24. Choy EHS, Isenberg DA, Garrood T. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. Arthritis Rheum. 2002;46:3143-3150.
25. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817-2829.
26. Vernallis A, Hudson KR, Heath JK. An antagonist for the leukemia inhibitory factor receptor inhibits leukemia inhibitory factor, ardiotrophin-1, ciliary neurotrophic factor, and oncostatin M. J. Biol. Chem. 1997;272:26947-26952.
27. Hudson KR, Vernallis AB, Heath JK. Characterization of the receptor binding site of human leukemia inhibitory factor and creation of antagonists. J. Biol. Chem. 1996;271:11971-11978.
28. Fairlie WD, Uboldi AD, McCoubrie JE, Wang CC, Lee EF, Yao S, De Souza DP, Mifsud S, Metcalf D, Nicola NA, Norton RS, Baca M. Affinity maturation of leukemia inhibitory factor and conversion to potent antagonists of signalling. J. Biol. Chem. 2004;279:2125-2134.
29. Smith DB, Johnson KS. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 1998;15:31-40.
30. Gearing GP, Ziegler SF, Comeau MR, Friend D, Thoma B, Cosman D, Park L, Mosely B. Proliferative responses and binding properties of hematopoietic cells transfected with low-affinity receptors for leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor. Proc. Natl. Acad. Sci. USA 1994;91:1119-1123.
31. Bergman I, Loxley R. Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal. Chem. 1963;35:1961-1965.
32. Cawston TE, Ellis AT, Humm G, Lean E, Ward D, Curry V. Interleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture. Biochem. Biophys. Res. Commun. 1995;215:377-385.
33. Piquet-Pellorce C, Grey L, Mereau A, Heath JK. Are LIF and related cytokines functionally equivalent? Exp. Cell Res. 1994;213;340-347.
34. Thoma B, Bird TA, Friend DJ, Gearing DP, Dower SK. Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes. J. Biol. Chem. 1994;269:6215-6222.
35. Cawston TE, Curry VA, Summers CA, Clark IM, Riley GP, Life PF, Spaull JR, Goldring MB, Koshy PJT, Rowan AD, Shingleton WD. The role of OSM in animal and human connective tissue turnover and its localization within the rheumatoid joint. Arthritis Rheum. 1998;41:1760-1771.
36. Rowan AD, Koshy PJ, Shingleton WD, Degnan BA, Heath JK, Vernallis AB, Spaull JR, Life PF, Hudson K, Cawston TE. Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis Rheum. 2001;44:1620-1632.
37. Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, Wythe H, Thomson D, Kishimoto T. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res. Ther. 2005;7:R1281-1288.
38. Bell M, Carroll GJ, Chapman H, Layton M, Mills J. Leukemia inhibitory factor (LIF) binding protein attenuates the phlogistic and abolishes the chondral effects of LIF in goat joints. J. Rheumatol. 1997;24:2394-2402.
39. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761-1769.
40. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int. Immunopharmacol. 2005;5:1731-1740.